[{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Infinant Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinant Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Infinant Health \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ First Wave BioPharma"},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avexegen Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Alvogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alvogen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ Inapplicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kratom Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sciences \/ Inapplicable"}]

Find Novel Gastroenterology Drugs in Clinical Development

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

BIO International Convention

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Capeserod

Therapeutic Area : Gastroenterology

Study Phase : Undisclosed

Sponsor : First Wave BioPharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

Details : Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications.

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

September 14, 2023

Lead Product(s) : Capeserod

Therapeutic Area : Gastroenterology

Highest Development Status : Undisclosed

Sponsor : First Wave BioPharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Tilray

Canada

WRIB

Not Confirmed

03

Infinant Health

U.S.A

German Wound Congress

Not Confirmed

04

Alvogen

U.S.A

German Wound Congress

Not Confirmed

05

Adial Pharmaceuticals

U.S.A

German Wound Congress

Not Confirmed

06

Tauriga Sciences

U.S.A

German Wound Congress

Not Confirmed

07

Hoth Therapeutics

U.S.A

German Wound Congress

Not Confirmed

08

Avexegen Therapeutics

U.S.A

German Wound Congress

Not Confirmed

09

Allakos

U.S.A

German Wound Congress

Not Confirmed